Report of the UK Cystic Fibrosis Trust Antibiotic Working Group

57. Ballestero S, Virseda I, Escobar H, Suarez L, Baquero F. Stenotrophomonas maltophilia in cystic fibrosis patients.Eur J Clin Microbiol Infect Dis 1995;14:728–9.58. Denton M, Todd NJ, Littlewood JM. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonasmaltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996;15:402–5.59. Denton M, Todd NJ, Littlewood JM. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonasmaltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996;15:402–5.60. Talmaciu I, Varlotta L, Mortensen J, Schidlow DV. Risk factors for emergence of Stenotrophomonas maltophilia incystic fibrosis. Pediatr Pulmonol 2000;30:10–5.61. Valdezate S, Vindel A, Maiz L, Baquero F, Escobar H, Canton R. Persistence and variability of Stenotrophomonasmaltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerg Infect Dis 2001;7:113–22.62. Marchac V, Equi A, Bihan-Benjamin C, Hodson M, Bush A. Case-control study of Stenotrophomonas maltophiliaacquisition in cystic fibrosis patients. Eur Respir J 2004;23:98–102.63. Denton M,.Kerr KG. Molecular epidemiology of Stenotrophomonas maltophilia isolated from cystic fibrosispatients. J Clin Microbiol 2002;40:1884.64. Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME et al. Home-use nebulizers: apotential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patientswith cystic fibrosis.[erratum appears in J Clin Microbiol 1996 Jun;34(6):1601]. J Clin Microbiol 1996;34:584–7.65. Denton M, Rajgopal A, Mooney L, Qureshi A, Kerr KG, Keer V et al. Stenotrophomonas maltophilia contaminationof nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. J Hosp Infect 2003;55:180–3.66. Denton M,.Kerr KG. Molecular epidemiology of Stenotrophomonas maltophilia isolated from cystic fibrosispatients. J Clin Microbiol 2002;40:1884.67. Krzewinski JW, Nguyen CD, Foster JM, Burns JL. Use of random amplified polymorphic DNA PCR to examineepidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients withcystic fibrosis.[see comment]. J Clin Microbiol 2001;39:3597–602.68. Vu-Thien H, Moissenet D, Valcin M, Dulot C, Tournier G, Garbarg-Chenon A. Molecular epidemiology ofBurkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center. Eur JClin Microbiol Infect Dis 1996;15:876–9.69. Karpati F, Malmborg AS, Alfredsson H, Hjelte L, Strandvik B. Bacterial colonisation with Xanthomonasmaltophilia--a retrospective study in a cystic fibrosis patient population. Infection 1994;22:258–63.70. Gladman G, Connor PJ, Williams RF, David TJ. Controlled study of Pseudomonas cepacia and Pseudomonasmaltophilia in cystic fibrosis. Arch Dis Child 1992;67:192–5.71. Demko CA, Stern RC, Doershuk CF. Thirteen year experience with Xanthomonas maltophilia in patients withcystic fibrosis. Pediatr Pulmonol 1995;Suppl 12:244.72. Demko CA, Stern RC, Doershuk CF. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence.Pediatr Pulmonol 1998;25:304–8.73. Valdezate S, Vindel A, Maiz L, Baquero F, Escobar H, Canton R. Persistence and variability of Stenotrophomonasmaltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerg Infect Dis 2001;7:113–22.74. Ballestero S, Virseda I, Escobar H, Suarez L, Baquero F. Stenotrophomonas maltophilia in cystic fibrosis patients.Eur J Clin Microbiol Infect Dis 1995;14:728–9.75. Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survivalof patients with cystic fibrosis. Am J Respir Crit Care Med 2002;166:356–61.76. Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. Association between Stenotrophomonasmaltophilia and lung function in cystic fibrosis. Thorax 2004;59:955–9.77. Denton M,.Kerr KG. Molecular epidemiology of Stenotrophomonas maltophilia isolated from cystic fibrosispatients. J Clin Microbiol 2002;40:1884.78. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies ofStenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother2004;48:168–71.79. Insa R, Cercenado E, Goyanes MJ, Morente A, Bouza E. In vitro activity of tigecycline against clinical isolates ofAcinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007;59:583-5.80. Denton M,.Kerr KG. Molecular epidemiology of Stenotrophomonas maltophilia isolated from cystic fibrosispatients. J Clin Microbiol 2002;40:1884.81. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies ofStenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother2004;48:168–71.Cystic Fibrosis Trust 7.10March 2009